TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Scancell Holdings ( (GB:SCLP) ) has provided an update.
Scancell Holdings plc has reported positive results from its Phase 2 SCOPE trial, demonstrating that iSCIB1+ in combination with checkpoint inhibitors could set a new standard for treating advanced melanoma, showing a progression-free survival rate of 78% at 11 months. The company is accelerating development plans for iSCIB1+, including regulatory and partnering discussions, with randomized studies anticipated to begin in 2026. Additionally, early results from the ModiFY trial indicate that Modi-1 improves response rates in head and neck cancer. Scancell has also strengthened its leadership team and secured a second commercial license with Genmab, highlighting its strategic growth and potential for future milestones.
Spark’s Take on GB:SCLP Stock
According to Spark, TipRanks’ AI Analyst, GB:SCLP is a Neutral.
Scancell Holdings’ overall stock score is heavily influenced by its poor financial performance, characterized by zero revenue and significant losses. However, recent positive clinical trial data and strategic developments in cancer vaccine trials provide a counterbalance, indicating potential for future growth. Technical indicators suggest a mixed trend with short-term bullish momentum, though overbought conditions warrant caution. Valuation remains unattractive, reflecting ongoing financial challenges. Overall, while there are promising developments in the pipeline, the company’s current financial challenges necessitate caution.
To see Spark’s full report on GB:SCLP stock, click here.
More about Scancell Holdings
Scancell Holdings plc is a clinical stage biotechnology company focused on developing targeted off-the-shelf active immunotherapies to generate safe and long-lasting tumor-specific immunity. Their lead product, iSCIB1+, from the DNA ImmunoBody® platform, has shown significant potential in treating advanced melanoma. Another key product, Modi-1, from the Moditope® platform, is under investigation for a range of solid tumors. Scancell has also established a subsidiary, GlyMab Therapeutics Ltd., to develop high affinity GlyMab® antibodies targeting tumor-specific glycans.
Average Trading Volume: 895,300
Technical Sentiment Signal: Sell
Current Market Cap: £90.29M
See more insights into SCLP stock on TipRanks’ Stock Analysis page.